{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T02:32:34Z","timestamp":1774319554044,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T00:00:00Z","timestamp":1723939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009228","name":"Region Orebro lan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009228","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ctro.2024.100846","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T09:15:31Z","timestamp":1724404531000},"page":"100846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Moderately hypofractionated prostate-only versus whole-pelvis radiotherapy for high-risk prostate cancer: A retrospective real-world single-center cohort study"],"prefix":"10.1016","volume":"48","author":[{"given":"Jenny","family":"Kahlmeter Brandell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6059-0194","authenticated-orcid":false,"given":"Antonis","family":"Valachis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Ugge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3916-8041","authenticated-orcid":false,"given":"Daniel","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengt","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2024.100846_b0005","unstructured":"EAU Guidelines: EAU Guidelines Office, Arnhem, The Netherlands; 2024 [Edn. presented at the EAU Annual Congress Paris]. Available from: https:\/\/uroweb.org\/eau-guidelines."},{"key":"10.1016\/j.ctro.2024.100846_b0010","unstructured":"National Comprehensive Cancer Network. Prostate Cancer (Version 3.2024) [Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"issue":"34","key":"10.1016\/j.ctro.2024.100846_b0015","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1200\/JCO.2006.10.5171","article-title":"Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01","volume":"25","author":"Pommier","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2024.100846_b0020","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ijrobp.2016.06.2455","article-title":"Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study","volume":"96","author":"Pommier","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.ctro.2024.100846_b0025","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1200\/JCO.2003.05.004","article-title":"Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: radiation therapy oncology group 9413","volume":"21","author":"Roach","year":"2003","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctro.2024.100846_b0030","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ctro.2024.100846_b0035","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from Phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctro.2024.100846_b0040","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/JU.0000000000002455","article-title":"Survival outcomes in men with unfavorable intermediate-risk and high-risk prostate cancer treated with prostate-only versus whole pelvic radiation therapy","volume":"207","author":"Andruska","year":"2022","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ctro.2024.100846_b0045","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ijrobp.2019.09.044","article-title":"External beam radiation therapy (EBRT) and high-dose-rate (HDR) brachytherapy for intermediate and high-risk prostate cancer: the impact of EBRT volume","volume":"106","author":"Tharmalingam","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctro.2024.100846_b0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.eururo.2019.03.022","article-title":"Prostate-only versus whole-pelvis radiation with or without a brachytherapy boost for gleason grade group 5 prostate cancer: a retrospective analysis","volume":"77","author":"Sandler","year":"2020","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ctro.2024.100846_b0055","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.ijrobp.2015.09.006","article-title":"Survival outcomes of whole-pelvic versus prostate-only radiation therapy for high-risk prostate cancer patients with use of the national cancer data base","volume":"93","author":"Amini","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ctro.2024.100846_b0060","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/COC.0000000000000285","article-title":"Impact of radiation therapy dose escalation on prostate cancer outcomes and toxicities","volume":"41","author":"Zaorsky","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2024.100846_b0065","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0360-3016(94)90138-4","article-title":"Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer","volume":"28","author":"Roach","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ctro.2024.100846_b0070","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.ijrobp.2022.04.008","article-title":"Meta-analysis of elective pelvic nodal irradiation using moderate hypofractionation for high-risk prostate cancer","volume":"113","author":"Viani","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"10.1016\/j.ctro.2024.100846_b0075","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO Guidance for Reporting Oncology real-World evidence (GROW)","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol"},{"issue":"3 Suppl","key":"10.1016\/j.ctro.2024.100846_b0080","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ijrobp.2009.09.040","article-title":"Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues","volume":"76","author":"Bentzen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctro.2024.100846_b0085","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijrobp.2008.10.086","article-title":"Dose-volume relationships for acute bowel toxicity in patients treated with pelvic nodal irradiation for prostate cancer","volume":"75","author":"Fiorino","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.ctro.2024.100846_b0090","doi-asserted-by":"crossref","first-page":"282","DOI":"10.5114\/jcb.2014.45586","article-title":"The impact of activating source dwell positions outside the CTV on the dose to treated normal tissue volumes in TRUS guided 3D conformal interstitial HDR brachytherapy of prostate cancer","volume":"6","author":"Karlsson","year":"2014","journal-title":"J Contemp Brachytherapy"},{"issue":"5","key":"10.1016\/j.ctro.2024.100846_b0095","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ctro.2024.100846_b0100","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/165019702760279242","article-title":"Life satisfaction in 18- to 64-year-old Swedes: in relation to gender, age, partner and immigrant status","volume":"34","author":"Fugl-Meyer","year":"2002","journal-title":"J Rehabil Med"},{"issue":"2","key":"10.1016\/j.ctro.2024.100846_b0105","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/16501970306119","article-title":"Life satisfaction in 18- to 64-year-old Swedes: in relation to education, employment situation, health and physical activity","volume":"35","author":"Melin","year":"2003","journal-title":"J Rehabil Med"},{"issue":"4","key":"10.1016\/j.ctro.2024.100846_b0110","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctro.2024.100846_b0115","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijrobp.2020.08.034","article-title":"NRG oncology updated international consensus atlas on pelvic lymph node volumes for intact and postoperative prostate cancer","volume":"109","author":"Hall","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctro.2024.100846_b0120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.eururo.2016.07.043","article-title":"Patterns of lymph node failure after dose-escalated radiotherapy: implications for extended pelvic lymph node coverage","volume":"71","author":"Spratt","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctro.2024.100846_b0125","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.radonc.2019.08.027","article-title":"ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer","volume":"141","author":"Ghadjar","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2024.100846_b0130","doi-asserted-by":"crossref","unstructured":"Sveistrup J, af Rosensch\u00f6ld PM, Deasy JO, Oh JH, Pommer T, Petersen PM, et al. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Radiat Oncol. 2014; 9: 44.","DOI":"10.1186\/1748-717X-9-44"},{"key":"10.1016\/j.ctro.2024.100846_b0135","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.radonc.2019.12.006","article-title":"Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): A randomised trial","volume":"145","author":"Murthy","year":"2020","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2024.100846_b0140","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ijrobp.2018.10.003","article-title":"Toxicity and patient-reported outcomes of a phase 2 randomized trial of prostate and pelvic lymph node versus prostate only radiotherapy in advanced localised prostate cancer (PIVOTAL)","volume":"103","author":"Dearnaley","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100846_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2024.03.023","article-title":"Late urinary toxicity and quality of life with pelvic radiation therapy for high-risk prostate cancer: dose-effect relations in the POP-RT randomized phase 3 trial","author":"Maitre","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100846_b0150","article-title":"Is ultrahypofractionated whole pelvis radiation therapy (WPRT) as well tolerated as conventionally fractionated WPRT in patients With prostate cancer? Early results from the HOPE trial","author":"Mendez","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.ctro.2024.100846_b0155","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ijrobp.2023.02.054","article-title":"A randomized feasibility trial of stereotactic prostate radiation therapy with or without elective nodal irradiation in high-risk localized prostate cancer (SPORT Trial)","volume":"117","author":"Houlihan","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ctro.2024.100846_b0160","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2022.05.050","article-title":"Acute and late adverse effects of prostate-only or pelvic stereotactic radiation therapy in prostate cancer: a comparative study","volume":"114","author":"Murthy","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"27","key":"10.1016\/j.ctro.2024.100846_b0165","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer","volume":"35","author":"Xie","year":"2017","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ctro.2024.100846_b0170","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.19.03114","article-title":"Event-free survival, a prostate-specific antigen-based composite end point, is not a surrogate for overall survival in men with localized prostate cancer treated with radiation","volume":"38","author":"Xie","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240563082400123X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240563082400123X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T11:13:47Z","timestamp":1728126827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240563082400123X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":34,"alternative-id":["S240563082400123X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2024.100846","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Moderately hypofractionated prostate-only versus whole-pelvis radiotherapy for high-risk prostate cancer: A retrospective real-world single-center cohort study","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2024.100846","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100846"}}